Naeem Fariha, McCleery Jenny, Hietamies Tuuli M, Abakar Ismail Fatene, Clinton Stephanie, O'Mahony Aoife, Ponce Oscar J, Quinn Terry J
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Oxford Health NHS Foundation Trust, Banbury, UK.
Cochrane Database Syst Rev. 2024 Dec 19;12(12):CD013725. doi: 10.1002/14651858.CD013725.pub2.
Dementia is a chronic and progressive clinical syndrome that can present with a range of cognitive and behavioural symptoms. Global prevalence is projected to increase due to ageing populations, particularly in resource-limited settings, with significant associated health and social care costs. There is a critical need for accurate cognitive assessment as part of the diagnostic workup for dementia. Although self-administered cognitive assessment tools are not diagnostic, they can be used to assess cognition. The role of these tests is uncertain, and their diagnostic test accuracy remains unclear, but they may be useful tools in circumstances where face-to-face assessment may be difficult.
Primary objective To assess the test accuracy of any self-administered cognitive assessment tool for the diagnosis of any form of dementia in any setting, including community and secondary health care. Secondary objectives To identify: the quality and quantity of the research evidence describing test accuracy of self-administered testing; sources of heterogeneity in the test accuracy described; and gaps in the evidence where further research is required.
We searched MEDLINE (Ovid SP), Embase (Ovid), Web of Science - BIOSIS Citation Index, PsycINFO (Ovid), LILACS (BIREME), and CINAHL (EBSCO). The most recent searches were run on 2 November 2022.
We included cross-sectional studies investigating the accuracy of a self-administered cognitive assessment tool. We included all settings, including community and secondary health care. The target condition of interest was a clinical diagnosis of dementia, therefore, we included only studies where the index test was administered alongside a reference standard clinical assessment. Our population of interest was any adult (over 18 years of age).
Two review authors independently reviewed included studies, assessed risk of bias using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, and extracted data. We obtained information on study design and participant characteristics, setting of index test, details of index text, reference standard used, and results reported as sensitivity and specificity. We performed a meta-analysis on three studies that used the same threshold score.
The review included 11 eligible studies, with a total of 2303 participants, which evaluated the diagnostic test accuracy of six different self-administered cognitive-assessment tools. The studies were conducted in Europe, North America, and South Korea within a variety of community and healthcare settings. Our quality assessment found that four studies had a low risk of bias across all domains. Six studies had a high or unclear risk of bias due to patient selection, with concerns around lack of a clear sampling strategy or exclusion criteria, or both. Six studies had a high or unclear risk of bias with regard to the index test due to lack of information about how the test was conducted and evaluated. For the diagnosis of dementia, sensitivity of self-administered cognitive assessment tools ranged from 55% to 100% and specificity ranged from 45% to 100%. Three studies described the diagnostic test accuracy of Test Your Memory at a threshold of 42/50. Quantitative meta-analysis estimated a summary point with 94% sensitivity (95% confidence interval (CI) 90% to 96%) and 66% specificity (95% CI 45% to 82%) at this threshold.
AUTHORS' CONCLUSIONS: There is insufficient evidence to recommend the use of any single self-administered cognitive assessment tool. The tools had test accuracy scores that are similar to the range seen with standard pencil and paper cognitive screening tests conducted by clinicians. Further research on the optimal test and threshold score, and how that may be impacted by setting, language, and educational level is needed.
痴呆是一种慢性进行性临床综合征,可表现出一系列认知和行为症状。由于人口老龄化,全球患病率预计将会上升,尤其是在资源有限的地区,这会带来巨大的相关健康和社会护理成本。作为痴呆诊断检查的一部分,准确的认知评估至关重要。尽管自我管理的认知评估工具不能用于诊断,但可用于评估认知。这些测试的作用尚不确定,其诊断测试准确性仍不明确,但在面对面评估可能困难的情况下,它们可能是有用的工具。
主要目的是评估任何自我管理的认知评估工具在任何环境(包括社区和二级医疗保健)中诊断任何形式痴呆的测试准确性。次要目的是确定:描述自我管理测试准确性的研究证据的质量和数量;所描述的测试准确性中的异质性来源;以及需要进一步研究的证据空白。
我们检索了MEDLINE(Ovid SP)、Embase(Ovid)、科学网 - BIOSIS引文索引、PsycINFO(Ovid)、LILACS(BIREME)和CINAHL(EBSCO)。最近一次检索于2022年11月2日进行。
我们纳入了调查自我管理认知评估工具准确性的横断面研究。我们纳入了所有环境,包括社区和二级医疗保健。感兴趣的目标疾病是痴呆的临床诊断,因此,我们仅纳入了将指标测试与参考标准临床评估同时进行的研究。我们感兴趣的人群是任何成年人(18岁以上)。
两位综述作者独立审查纳入的研究,使用诊断准确性研究质量评估(QUADAS - 2)工具评估偏倚风险,并提取数据。我们获取了有关研究设计和参与者特征、指标测试的环境、指标测试的详细信息、使用的参考标准以及报告为敏感性和特异性的结果的信息。我们对三项使用相同阈值分数的研究进行了荟萃分析。
该综述纳入了11项符合条件的研究,共有2303名参与者,评估了六种不同自我管理认知评估工具的诊断测试准确性。这些研究在欧洲、北美和韩国的各种社区和医疗保健环境中进行。我们的质量评估发现,四项研究在所有领域的偏倚风险较低。六项研究因患者选择存在高或不明确的偏倚风险,原因是担心缺乏明确的抽样策略或排除标准,或两者皆有。六项研究因缺乏关于测试如何进行和评估的信息,在指标测试方面存在高或不明确的偏倚风险。对于痴呆的诊断,自我管理认知评估工具的敏感性范围为55%至100%,特异性范围为45%至100%。三项研究描述了在42/50的阈值下“测试你的记忆力”的诊断测试准确性。定量荟萃分析估计在此阈值下汇总点的敏感性为94%(95%置信区间(CI)90%至96%),特异性为66%(95%CI 45%至82%)。
没有足够的证据推荐使用任何单一的自我管理认知评估工具。这些工具的测试准确性得分与临床医生进行的标准纸笔认知筛查测试的得分范围相似。需要对最佳测试和阈值分数以及其可能如何受到环境、语言和教育水平影响进行进一步研究。